MiniMed
Insulin pumps, continuous glucose monitoring and automated insulin delivery.
The record
- Vertical
- Metabolic Health
- Sub-segment
- Insulin delivery and CGM
- Product type
- Device
- Stage
- Public
- Headquarters
- Northridge, CA, United States
- Region
- North America
- Ticker
- NASDAQ: MMED
What they do
MiniMed is a diabetes technology company listed on Nasdaq as MMED. It develops insulin pumps, continuous glucose monitoring and automated insulin delivery. On 16 November 2026 it announced FDA clearance of MiniMed Fit, its first tubeless pump, for people with Type 1 or Type 2 diabetes aged seven and older. The pump has a 300-unit capacity and up to seven days of wear, subject to insulin requirements. A phased US rollout is expected in spring 2027; clearance does not mean it is already commercially available.
History and progression
How MiniMed got here, step by step.
16 November 2026
MiniMed Fit FDA clearance
FDA clearance was announced for MiniMed Fit, a tubeless pump with up to seven-day wear and 300-unit capacity. A phased US rollout is planned for spring 2027.
Recent news
16 November 2026
MiniMed announcement16 November 2026
Que Dallara, CEO
Related companies